Anavex Life Sciences 미래 성장

Future 기준 확인 3/6

Anavex Life Sciences은 연간 수입과 매출이 각각 47.1%와 50.6% 증가할 것으로 예상되고 EPS는 연간 52.9%만큼 증가할 것으로 예상됩니다.

주요 정보

47.1%

수익 성장률

52.9%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	50.6%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	26 Dec 2024

최근 미래 성장 업데이트

Recent updates

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Dec 25

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 24

Anavex: EU Approval Application Is A Precipitous Moment

Dec 08

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Nov 11

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Nov 05

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Oct 08

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

수익 및 매출 성장 예측

NasdaqGS:AVXL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2027	543	360	822	610	2
9/30/2026	334	453	542	738	2
9/30/2025	N/A	-53	-60	222	3
9/30/2024	N/A	-43	-31	-31	N/A
6/30/2024	N/A	-42	-30	-30	N/A
3/31/2024	N/A	-41	-32	-32	N/A
12/31/2023	N/A	-43	-29	-29	N/A
9/30/2023	N/A	-48	-28	-28	N/A
6/30/2023	N/A	-52	-26	-26	N/A
3/31/2023	N/A	-53	-25	-25	N/A
12/31/2022	N/A	-50	-27	-27	N/A
9/30/2022	N/A	-48	-24	-24	N/A
6/30/2022	N/A	-45	-28	-28	N/A
3/31/2022	N/A	-43	-28	-28	N/A
12/31/2021	N/A	-41	-26	-26	N/A
9/30/2021	N/A	-38	-30	-30	N/A
6/30/2021	N/A	-32	-29	-29	N/A
3/31/2021	N/A	-28	-25	-25	N/A
12/31/2020	N/A	-28	-23	-23	N/A
9/30/2020	N/A	-26	-21	-21	N/A
6/30/2020	N/A	-26	-18	-18	N/A
3/31/2020	N/A	-26	-21	-21	N/A
12/31/2019	N/A	-26	-20	-20	N/A
9/30/2019	N/A	-26	-19	-19	N/A
6/30/2019	N/A	-26	-20	-20	N/A
3/31/2019	N/A	-23	-15	-15	N/A
12/31/2018	N/A	-20	-13	-13	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-17	N/A	-11	N/A
3/31/2018	N/A	-18	N/A	-12	N/A
12/31/2017	N/A	-14	N/A	-9	N/A
9/30/2017	N/A	-13	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-9	N/A
3/31/2017	N/A	-13	N/A	-8	N/A
12/31/2016	N/A	-14	N/A	-9	N/A
9/30/2016	N/A	-15	N/A	-9	N/A
6/30/2016	N/A	-14	N/A	-9	N/A
3/31/2016	N/A	-16	N/A	-8	N/A
12/31/2015	N/A	-15	N/A	-7	N/A
9/30/2015	N/A	-12	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-12	N/A	-3	N/A
12/31/2014	N/A	-11	N/A	-3	N/A
9/30/2014	N/A	-10	N/A	-3	N/A
6/30/2014	N/A	-5	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AVXL 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AVXL (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AVXL 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AVXL 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: AVXL 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AVXL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/26 03:49
장 마감 주가	2024/12/26 00:00
수익	2024/09/30
연간 수익	2024/09/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Anavex Life Sciences Corp. 14 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Caroline Palomeque	Berenberg
Yun Zhong	BTIG
Charles Duncan	Cantor Fitzgerald & Co.

Anavex Life Sciences 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Forecast breakeven date pushed back to 2026

Forecast breakeven date moved forward to 2025

Price target decreased by 26% to US$40.00

Forecast to breakeven in 2025

Price target increased by 19% to US$47.00

Price target increased by 30% to US$41.67

Recent updates

Forecast breakeven date pushed back to 2026

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Anavex Life Sciences Corp. Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Anavex Life Sciences Corp. to Report Q4, 2024 Results on Dec 23, 2024

Anavex: EU Approval Application Is A Precipitous Moment

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

New minor risk - Share price stability

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

President notifies of intention to sell stock

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Price target decreased by 26% to US$40.00

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

New major risk - Revenue and earnings growth

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Chairman notifies of intention to sell stock

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Forecast to breakeven in 2025

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Price target increased by 19% to US$47.00

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Price target increased by 30% to US$41.67

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Price target decreased to US$33.25

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

Independent Director exercised options and sold US$407k worth of stock